论文部分内容阅读
目的 探讨β受体阻滞剂美托洛尔治疗充血性心力衰竭(CHF)患者的临床疗效。方法 62 例患者均在应用强心、利尿、扩血管药物的同时,给予美托洛尔,初始剂量6.25mg,每日2次,每1周增加剂量1倍,最大剂量50mg,每日2次,至少观察4周。结果 应用美托洛尔前心率(110±6)次/min、收缩压(156.7±15.5)mmHg、舒张压(103.4±13.2)mmHg;治疗4 周后心率(75±7)次/min、收缩压(115.6±13.6)mmHg、舒张压(71.3±11.8)mmHg;治疗前后比较有显著性差异(P<0.01)。心功能变化情况:心功能改善Ⅰ级32 例、改善Ⅱ级10 例、改善Ⅲ级3例,有效率66.8%。结论 β受体阻滞剂对CHF有效,可改善心功能和临床症状,提高存活率和生活质量,降低病死率。
Objective To investigate the clinical efficacy of β-blocker metoprolol in patients with congestive heart failure (CHF). Methods Sixty-two patients were given metoprolol while using cardiotonic, diuretic and vasodilator drugs. The initial dose was 6.25mg twice daily, and the dosage was doubled every week, the maximum dose was 50mg twice daily , Observed for at least 4 weeks. Results Before metoprolol treatment, heart rate (110 ± 6) beats / min, systolic blood pressure (156.7 ± 15.5) mmHg, and diastolic blood pressure (103.4 ± 13.2) (115.6 ± 13.6) mmHg and diastolic blood pressure (71.3 ± 11.8) mmHg respectively. There was significant difference between before and after treatment (P <0.01). Changes in cardiac function: heart function improved grade Ⅰ in 32 cases, grade Ⅱ improved in 10 cases, grade Ⅲ improved in 3 cases, the effective rate of 66.8%. Conclusion β blockers are effective for CHF, improve cardiac function and clinical symptoms, improve survival rate and quality of life, reduce mortality.